3ui7: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Discovery of orally active pyrazoloquinoline as a potent PDE10 inhibitor for the management of schizophrenia== | ==Discovery of orally active pyrazoloquinoline as a potent PDE10 inhibitor for the management of schizophrenia== | ||
<StructureSection load='3ui7' size='340' side='right' caption='[[3ui7]], [[Resolution|resolution]] 2.28Å' scene=''> | <StructureSection load='3ui7' size='340' side='right' caption='[[3ui7]], [[Resolution|resolution]] 2.28Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[3ui7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[3ui7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3UI7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3UI7 FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=C1L:6-METHOXY-3,8-DIMETHYL-4-(MORPHOLIN-4-YLMETHYL)-1H-PYRAZOLO[3,4-B]QUINOLINE'>C1L</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=C1L:6-METHOXY-3,8-DIMETHYL-4-(MORPHOLIN-4-YLMETHYL)-1H-PYRAZOLO[3,4-B]QUINOLINE'>C1L</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">PDE10A ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">PDE10A ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3ui7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3ui7 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3ui7 RCSB], [http://www.ebi.ac.uk/pdbsum/3ui7 PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3ui7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3ui7 OCA], [http://pdbe.org/3ui7 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3ui7 RCSB], [http://www.ebi.ac.uk/pdbsum/3ui7 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3ui7 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
| Line 17: | Line 18: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 3ui7" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== | ||
| Line 24: | Line 26: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Human]] | ||
[[Category: Greenlee, W J]] | [[Category: Greenlee, W J]] | ||
[[Category: Ho, G]] | [[Category: Ho, G]] | ||
Revision as of 01:03, 5 August 2016
Discovery of orally active pyrazoloquinoline as a potent PDE10 inhibitor for the management of schizophreniaDiscovery of orally active pyrazoloquinoline as a potent PDE10 inhibitor for the management of schizophrenia
Structural highlights
Function[PDE10_HUMAN] Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.[1] Publication Abstract from PubMedA series of pyrazoloquinoline analogs have been synthesized and shown to bind to PDE10 with high affinity. From the SAR study and our lead optimization efforts, compounds 16 and 27 were found to possess potent oral antipsychotic activity in the MK-801 induced hyperactive rat model. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.,Yang SW, Smotryski J, McElroy WT, Tan Z, Ho G, Tulshian D, Greenlee WJ, Guzzi M, Zhang X, Mullins D, Xiao L, Hruza A, Chan TM, Rindgen D, Bleickardt C, Hodgson R Bioorg Med Chem Lett. 2011 Nov 16. PMID:22142545[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||